Table 2.
Patient characteristics.
| Study (Publication Year) | n | Follow-Up, Years | Age | Gender M (%) F (%) |
||
|---|---|---|---|---|---|---|
| Glucocorticoid | Control | Glucocorticoid | Control | |||
| Call et al (2015) [19] | 144 | 1.2A | 65A | 67 A | 33 (47.8) 36 (52.2) |
43 (57.3) 32 (62.7) |
| Cata et al (2016) [20] | 1549 | 1–12 | 65.4 C | 63.5 C | 176 (40.1) 263 (59.9) |
603 (54.3) 507 (45.7) |
| De Oliveira et al (2014) [21] | 260 | 4–10 | 57 A | 58 A | 0 (0.0) 102 (100) |
0 (0.0) 158 (100) |
| Gan et al (2015) [22] | 100 | 3.75 B | 53.2 B | 50.1 B | 24 (48) 26 (52) |
28 (56) 22 (44) |
| Huang et al (2018) [23] | 588 | 6–10 | NA | NA | 374 (63.6) * 214 (36.4) * |
|
| Kim et al (2019) [24] | 2628 | 5–10 | 49.5 B | 50.1 B | 0 (0.0) 236 (100) |
0 (0.0) 2392 (100) |
| Lazzara et al (2018) [25] | 249 | 0–4.75 | 66 A | 69 A | 26 (42.6) 35 (57.4) |
110 (58.5) 78 (41.48) |
| Merk et al (2016) [26] | 309 | 4.3 (G) A 3.9 (C) A |
64 A | 66 A | 0 (0.0) 107 (100) |
0 (0.0) 202 (100) |
| Okazumi et al (2004) [27] | 37 | 3–8 | 61 B | 62 B | 18 (94.7) 1 (5.3) |
16 (88.9) 2 (0.1) |
| Sandini et al (2018) [28] | 679 | 2 A | 65 A | 67 A | 38 (32.5) 79 (67.5) |
284 (50.5) 278 (49.5) |
| Sato et al (2002) [29] | 66 | 1.5–4.5 | 62 B | 64 B | 29 (88) 4 (12) |
31 (94) 2 (6) |
| Shimada et al (2004) [30] | 141 | 3-12 | 64 A | 64 A | 66 (84.6) 12 (15.4) |
55 (87.3) 8 (12.7) |
| Singh et al (2014) [31] | 43 | 4.8–6.5 | 72 A | 71 A | 6 (30.0) 14 (70.0) |
13(56.5) 10(43.5) |
| Yano et al (2005) [32] | 40 | 5 | 63.5 B | 55.9 B | 17 (85.0) 3 (15.0) |
19 (95.0) 1 (5.0) |
| Yu et al (2015) [33] | 515 | 3–7 | 60 A | 59 A | 47 (63) 28 (37) |
250 (57) 190 (43) |
| Zhu et al (2017) [34] | 303 | 2.5–8.45 | 61 A,* | 101 (33.3) * 202 (66.7) * |
||
A Median, B Mean, * Numbers refer to overall population; Abbreviations: NA = not applicable; G = glucocorticoid group; C = control group.